Annovis Bio falls on delayed study results for Parkinson's therapy

Annovis Bio

24/01/2024 13:45

** Shares of drug developer Annovis Bio  ANVS.N  fall ~6% to
$10.95 premarket
    ** Co postpones the release of late-stage study data for its
lead canddiate buntanetap which is being studied in patients
with Parkinson's Disease
    ** The data announcement was initially set for the end of
Jan. 2024
    ** The adjustment is due to ongoing data cleaning efforts to
ensure the accuracy and reliability of the study results - ANVS
    ** ANVS shares fell ~9% in the last 12 months

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))